Novocure (NVCR) Scheduled to Post Earnings on Thursday

Novocure (NASDAQ:NVCR) is scheduled to be releasing its earnings data before the market opens on Thursday, February 22nd. Analysts expect Novocure to post earnings of ($0.11) per share for the quarter.

Novocure (NASDAQ NVCR) opened at $21.05 on Thursday. The company has a current ratio of 5.90, a quick ratio of 5.30 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $1,880.00 and a price-to-earnings ratio of -25.36. Novocure has a 12-month low of $6.75 and a 12-month high of $24.15.

A number of research analysts recently commented on NVCR shares. ValuEngine upgraded Novocure from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub cut Novocure from a “buy” rating to a “hold” rating in a research report on Thursday, January 25th. Zacks Investment Research cut Novocure from a “buy” rating to a “hold” rating in a research report on Saturday, January 13th. Mizuho restated a “buy” rating and issued a $25.00 price target on shares of Novocure in a research report on Friday, December 1st. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Novocure in a research report on Monday, November 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Novocure has an average rating of “Buy” and an average target price of $21.13.

In related news, General Counsel Todd Christopher Longsworth sold 11,630 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $24.00, for a total value of $279,120.00. Following the sale, the general counsel now directly owns 16,628 shares of the company’s stock, valued at $399,072. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Wilhelmus Cm Groenhuysen sold 28,868 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $21.03, for a total value of $607,094.04. Following the completion of the sale, the chief financial officer now directly owns 268,568 shares in the company, valued at $5,647,985.04. The disclosure for this sale can be found here. Insiders sold 483,092 shares of company stock worth $10,737,084 in the last 90 days. 16.70% of the stock is owned by company insiders.

WARNING: “Novocure (NVCR) Scheduled to Post Earnings on Thursday” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/15/novocure-nvcr-scheduled-to-post-earnings-on-thursday.html.

Novocure Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Earnings History for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply